IDEXX Laboratories is expected to report Q1 2026 revenue of $1.12 billion and earnings per share of $3.42, with the stock currently trading at $567.46 against a mean analyst price target of $751.00.
Investors are laser-focused on the Companion Animal Group (CAG) diagnostics organic recurring revenue growth, which is projected to rise between 8.5% and 10.5%.
This performance is critical as the company navigates a projected 2% decline in U.S. same-store clinical visits while attempting to drive higher price realization and premium instrument pull-through. Market participants will also evaluate the early international rollout of the Cancer Dx platform and the continued adoption momentum of the inVue Dx system.